4th of August 2024

Case study: >Your< Back Pain Capsules

An analysis of how our client launched our back pain product under their brand in an EU market and initiated a clinical study due to outstanding results and user feedback.

Our client, a medium-sized food supplement company from a country in the European Union, launched >Your< Back Pain Capsules in 2018. Their neuropathic supplement market was small but developing, with high market concentration. Due to outstanding physician and user feedback, a clinical trial on the product was initiated.

the case study.

Download the case study to discover how our client:

"*" indicates required fields

  • approached a neuropathic supplements market where the 2 leading companies held an 88% market share
  • increased their sell-out by 107%
  • initiated a clinical study due to outstanding user feedback

key results.

  • our client increased their sell-out by 107% in 2022
  • the number of yearly ordered units grew by 8,4% in 2023 and by an additional 4,7% in 2024 
  • due to the product’s market success, a clinical trial on the finished formulation was initiated and published in 2024

explore further.

>Your< Back Pain Capsules are a clinically supported private label food supplement for neuropathic pain
>Your< Back Pain Capsules

Proprietary complex targeting neuronal damage and pain relief.

Clinical trial on >Your< Back Pain Capsules

Our back pain product was proven to substantially improve standard physical therapy by significantly reducing pain severity and significantly increasing mobility in subjects with chronic back pain. Results were presented in a webinar, which is now available on demand.

"*" indicates required fields

"*" indicates required fields

PharmaLinea © 2025